Biosecurity

5min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Ginko CEO: Biosecurity is not just important in its own right, it's also into becoming fundamental to the economy itself. The tools that we are building to make biology easier to engineer are also the same tools that you can use to respond to biosecurity issues. Ginko has built a 500 person organization that's entirely focused on this goal of making biology easier to Engineer.

Moderna's Covid-19 vaccine would not have scaled without Ginkgo Bioworks. Reshma Shetty, co-founder and COO of Ginkgo – slated to go public via SPAC acquisition at a reported $15 billion valuation – explains how biotech innovation can build a better future now. Ginkgo's platform already serves industries from food and agriculture, to materials, to healthcare. Shetty acknowledges that engineering genes is a high stakes pursuit, and says Ginkgo is trying to pair the ambition of Silicon Valley with a "higher level of care" than consumer tech companies like social media have demonstrated. The key, Shetty says, is creating an unstable equilibrium – propelling progress but not at the expense of principles.

Read a transcript of this interview at: mastersofscale.com

Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.